Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and Chemoradiation
Yu Pu Yang, Austin Arrigo, Ankush Chandra, Chuling Zhuang, Mariana K. Najjar, Munazza Samar Khan, Dongqin Zhu, Antonio Dono, Roy Ervin Strowd III, Nitin Tandon, Jay‐Jiguang Zhu, Sigmund H. Hsu, Yoshua Esquenazi, Michael David Chan, Hui‐Wen Lo
This paper identifies tGLI1 as a mediator of GBM resistance to CDK4/6 inhibitors and shows that ketoconazole sensitizes GBM to CDK4/6 therapy and chemoradiation.
bioRxiv · Feb 20, 2025 · PreprintCancer Biology